<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495479</url>
  </required_header>
  <id_info>
    <org_study_id>OMN54-PC-02</org_study_id>
    <nct_id>NCT03495479</nct_id>
  </id_info>
  <brief_title>Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance</brief_title>
  <acronym>CAMPAS</acronym>
  <official_title>Phase IIA, Single-Center, Single-Arm Clinical Study of OMN54 (Aneustat) in Men Diagnosed With Prostate Cancer Being Followed by Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omnitura Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vancouver Prostate Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Omnitura Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the effects of OMN54 (Aneustat) in a population of men with indolent prostate&#xD;
      cancer who are otherwise healthy and free of significant co-morbidities and have chosen&#xD;
      active surveillance for disease management. The investigators will assess how OMN54 affects&#xD;
      PSA, overall tumor burden in addition to any changes in urinary flow. Other biomarkers will&#xD;
      be tested to follow disease evolution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2025</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Prostate Specific Antigen</measure>
    <time_frame>12 months</time_frame>
    <description>Quarterly assessment of serum Prostate Specific Antigen (PSA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Tumor Size</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in tumor size based on semi-annual MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Urinary Flow</measure>
    <time_frame>12 months</time_frame>
    <description>Quartelry assessment of patient urinary flow based on patient IPSS Questionnaire</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>OMN54 -Treated</arm_group_label>
    <description>Six-month, daily oral dosing in softgel capsules throughout the first 6 months of treat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMN54</intervention_name>
    <description>Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.</description>
    <arm_group_label>OMN54 -Treated</arm_group_label>
    <other_name>Aneustat(TM)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men diagnosed with early stage prostate cancer that elect to pursue active surveillance for&#xD;
        disease management and agree to take the study drug.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Localized prostate cancer suitable for active surveillance&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the prostate, with Gleason Score 6 or less&#xD;
             prostate cancer. No limit in the percentage of cancer in each core or percentage of&#xD;
             positive cores.&#xD;
&#xD;
          2. Male, 18 years or older&#xD;
&#xD;
          3. Able to swallow the soft gelatin capsule form of the drug which is ~6mm long.&#xD;
&#xD;
          4. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.&#xD;
&#xD;
          5. No previous treatment for prostate cancer (including hormonal therapy, radiation&#xD;
             therapy, surgery, or chemotherapy).&#xD;
&#xD;
          6. ECOG Performance Status 0 or 1.&#xD;
&#xD;
          7. Patient has elected Active Surveillance as preferred management plan for prostate&#xD;
             cancer.&#xD;
&#xD;
          8. Written informed consent obtained prior to any patient participation.&#xD;
&#xD;
          9. Participant is accessible and compliant for follow-up.&#xD;
&#xD;
         10. Prostate biopsy requirements:&#xD;
&#xD;
               1. If diagnosis was within one year of baseline visit, participant must have at&#xD;
                  least one biopsy with at least 10 cores.&#xD;
&#xD;
               2. If diagnosis was more than 1 year prior to baseline visit, participant must have&#xD;
                  a minimum of 2 biopsies, one of which must be within 2 years prior to baseline&#xD;
                  visit.&#xD;
&#xD;
         11. Voiding requirements: IPSS score of at least 15 and Qmax &lt; 15 cc/s.&#xD;
&#xD;
         12. Adequate hematopoietic function as demonstrated by:&#xD;
&#xD;
               -  hemoglobin of ≥ 9.0 g/dL without need for sustained blood transfusions&#xD;
&#xD;
               -  Platelet count ≥100,000 platelet/mm3 (100 x 109/L)&#xD;
&#xD;
               -  White Blood Cell (WBC) count ≥ 2.0 x109/L and Absolute Neutrophil Count (ANC)&#xD;
                  ≥1.5 x109/L&#xD;
&#xD;
         13. Adequate hepatobiliary function as demonstrated by:&#xD;
&#xD;
               -  Total bilirubin level within normal limits&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) levels within normal limits&#xD;
&#xD;
               -  Adequate renal function as demonstrated by creatinine level within normal limits&#xD;
                  or creatinine clearance within normal limits&#xD;
&#xD;
               -  Coagulation profile (PT, PTT, INR and TCT) within normal limits&#xD;
&#xD;
         14. If of reproductive capacity, willing to use an effective double barrier method of&#xD;
             birth control (i.e., latex condom, partner use of diaphragm, cervical cap, etc) during&#xD;
             the study and for 30 days after the last administration of OMN54&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwillingness or inability to undergo serial prostate biopsy or MRI.&#xD;
&#xD;
          2. History of other malignancies, except: adequately treated non-melanoma skin cancer or&#xD;
             adequately treated superficial bladder cancer (Ta) or other solid tumors curatively&#xD;
             treated with no evidence of disease for &gt; 5 years.&#xD;
&#xD;
          3. Previous surgical intervention for BPH&#xD;
&#xD;
          4. Active uncontrolled infection, including known history of HIV, hepatitis B or C&#xD;
&#xD;
          5. Concurrent uncontrolled hypertension&#xD;
&#xD;
          6. Congestive Heart Failure&#xD;
&#xD;
          7. Hepatic disease (cirrhosis, hepatitis, hepatocellular carcinoma or liver failure of&#xD;
             unknown etiology)&#xD;
&#xD;
          8. Renal disease (glomerulonephritis, nephropathy, polycystic kidney disease)&#xD;
&#xD;
          9. Patients requiring new treatment of BPH (either medical or surgical) are not eligible.&#xD;
&#xD;
         10. Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory&#xD;
             bowel disease), or significant bowel resection that would preclude adequate&#xD;
             absorption.&#xD;
&#xD;
         11. Known hypersensitivity to any of the three botanical constituents of Aneustat™&#xD;
             (OMN54); soy; any of the plants belonging to the Ganodermataceae family, e.g., reishi&#xD;
             mushroom (Ganoderma lucidum, lingzhi); any plants belonging to Labiatae or Lamiaceae&#xD;
             families, e.g., culinary herbs including basil, mint, rosemary, sage, savory,&#xD;
             marjoram, oregano, thyme, lavender, and perilla; or Aneustat™ (OMN54) excipients.&#xD;
&#xD;
         12. Concurrent administration, or exposure within 30 days, of:&#xD;
&#xD;
               -  Investigational drugs and devices&#xD;
&#xD;
               -  Chemotherapy&#xD;
&#xD;
               -  Radiation therapy&#xD;
&#xD;
               -  Immunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan So, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prostate Centre at Vancouver General Hospital</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>PC</keyword>
  <keyword>Active Surveillance</keyword>
  <keyword>Chemonaiive</keyword>
  <keyword>OMN54</keyword>
  <keyword>Aneustat (TM)</keyword>
  <keyword>PSA</keyword>
  <keyword>BPH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This is undecided and will be decided in consultation with the PI.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

